Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 318,36 € (+18,79 %). Medianen er 313,81 € (+17,09 %).
| Køb |
13 |
| Behold |
4 |
| Sælg |
1 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Ligand Pharmaceuticals expands royalty aggregator and raises earnings guidance
Ligand Pharmaceuticals reports that its royalty-aggregator model, introduced in 2022, is scaling and producing higher-margin, more predictable revenues; Q2 revenue rose 34% to $64 million and adjusted earnings per share increased 48% to $2.37. The acquisition of XOMA doubled the partnered portfolio to more than 220 programs and is expected to boost 2025 EPS by at least $1.50. Management raised its 2024 adjusted EPS guidance to $9.00–$9.50, sees several near- to mid-term approval catalysts (including FILSPARI, Palvella) and plans annual investments of $150–$250 million. At the same time the company warned of typical biotech risks such as clinical setbacks, reimbursement pressure and future patent expirations. » Mere på de.investing.com
Ligand Pharmaceuticals benefits from licensing-based business model and strong growth
Ligand Pharmaceuticals achieves high profitability through a pure licensing-and-royalties model that reduces the development risks typical of biotech. Strategic moves — including the multibillion-dollar acquisition of XOMA — and key product approvals are driving forecasted license revenues to grow by more than 23% annually over the next five years. The stock has rallied above $320 and is regarded as a fundamentally solid/quality investment. » Mere på finanzen.net
Ligand: license revenues rise 56%, adjusted EPS misses forecast
Ligand reported a 56% increase in license revenues for Q1 2026 to $43.0m, while adjusted earnings per share of $1.63 missed analysts’ expectation of $1.84. Total revenue rose to $51.7m but remained below the consensus of about $59.1m; Captisol and contract revenues also declined. The company emphasizes a strategic shift to a capital‑efficient licensing aggregator, holds roughly $780m in cash and expects the planned acquisition of XOMA to drive meaningful EPS effects and higher license revenues in 2026. Ligand raised its full‑year guidance and sees strong long‑term license growth, but acknowledges near‑term market and valuation risks. » Mere på de.investing.com
Ligand Pharmaceuticals misses Q1 forecasts, stock falls nearly 10% premarket
Ligand Pharmaceuticals reported adjusted Q1 EPS of $1.63 (expectation $1.84) and revenue of $51.72 million (expectation $59.07 million), both well below analyst estimates. The stock fell about 9.8% in premarket trading to $210. Despite the earnings miss, license revenues rose 56% to $43 million, and the company reaffirmed its long-term strategy and a full-year EPS target of $8.50–9.50. Management points to nearly $1 billion of available capital and emphasizes a focus on license growth and integrating acquisitions such as XOMA Royalty Corp. » Mere på de.investing.com
Arecor receives $0.5m milestone payment from Ligand
Arecor has received a $0.5 million commercial milestone payment from Ligand under a licensing agreement for AT220 and AT292. An upfront payment of $7.0 million was previously received, and a further $4.0 million is payable upon achievement of upcoming commercial milestones. Arecor expects an additional $0.5 million in the second half of 2026; $3.0 million remains tied to future milestones. According to CEO Sarah Howell, the funds are intended to accelerate development of AT278, with a Phase 2 study planned for H2 2026. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 69,52 mio. | 29,34 % |
| Bruttofortjeneste | 67,18 mio. | 13,02 % |
| Nettoresultat | -25,15 mio. | 125,17 % |
| EBITDA | -38,93 mio. | 130,58 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 5,35 mia. € |
Antal aktier | 20 mio. |
Højeste/laveste i 52 uger | 297,10 € - 159,99 € |
| Udbytte | Nej |
Beta | 1,03 |
P/E (PE Ratio) | 113,44 |
PEG (PEG Ratio) | 13,56 |
K/I (PB Ratio) | 6,10 |
P/S (PS Ratio) | 23,15 |
Virksomhedsprofil
Ligand Pharmaceuticals Incorporated, et biofarmaceutisk selskab, fokuserer på at udvikle eller erhverve teknologier, der hjælper farmaceutiske virksomheder med at opdage og udvikle medicin over hele verden. Selskabets kommercielle programmer omfatter Kyprolis og Evomela, som anvendes til behandling af multipel myelom; Veklury til behandling af moderat eller svær COVID-19; Teriparatide injektionsprodukt til osteoporose; Vaxneuvance til forebyggelse af invasiv sygdom forårsaget af Streptococcus pneumoniae; og Pneumosil, en pneumokok-konjugatvaccine til at hjælpe med at bekæmpe pneumokoklungebetændelse hos børn. Selskabet tilbyder også Rylaze, et rekombinant erwinia-asparaginase til behandling af akut lymfoblastisk leukæmi eller lymfoblastisk lymfom hos voksne og børnepatienter; samt Nexterone, en captisol-baseret formulering af amiodaron; og Zulresso, en captisol-baseret formulering af brexanolon til behandling af fødselsdepression. Derudover leverer det Noxafil-IV, en captisol-baseret formulering af posaconazol til intravenøs anvendelse; Duavee til behandling af postmenopausal osteoporose; Aziyo-porteføljen af kommercielle perikardiereparationsprodukter og CanGaroo envelope extracellular matrix-produkter; Exemptia til autoimmune sygdomme; Vivitra til brystkræft; Bryxta og Zybev til forskellige indikationer; og Minnebro til behandling af hypertension. Selskabets partner- og licensprogrammer, som er under klinisk udvikling, anvendes til behandling af kræft, anfald, diabetes, hjerte-kar-sygdomme, muskelnedbrydning, lever- og nyresygdomme og andre sygdomme. Desuden sælger det Captisol-materialer. Selskabet blev stiftet i 1987 og har hovedkvarter i Emeryville, Californien.
| Navn | Ligand Pharmaceuticals |
| CEO | Todd C. Davis |
| Hjemsted | Jupiter,
fl USA |
| Websted | |
| Sektor | Materialer |
| Branche | Kemikalier |
| Børsnotering | 18.11.1992 |
| Medarbejdere | 47 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | LGND |
Frankfurt | LGDN.F |
Düsseldorf | LGDN.DU |
SIX | LGDN.SW |
München | LGDN.MU |